Prescription Justice Awards U.S. Senator Elizabeth Warren with 5-Star Rating
U.S. Senator Elizabeth Warren (D-MA) was awarded a 5-Star rating from Prescription Justice for her full support of the Prescription Justice Policy Platform. These are commonsense and necessary policies to lower drug prices here at home and expand access to lower cost medication from pharmacies in other countries.
Prescription Justice assigns ratings to members of Congress based on their support of the organization’s policy platform. The Prescription Justice Policy Platform is based on the reality that America is suffering from a crisis of high drug prices. To end that crisis, we call for Congress and the administration to:
•End the ban on Medicare drug price negotiations.
•End pay-for-delay deals between brand and generic companies that prevent lower cost medications from coming to market.
•Legalize importation of lower-cost medication from Canada and other countries with similarly strict pharmaceutical regulations.
•Promote the use of reasonable, commonsense, and compassionate enforcement discretion to permit individuals to import small quantities of affordable medication to fill prescriptions.
Senator Warren’s 5-Star rating reflects her full commitment to lowering skyrocketing prescription drug costs in America, one of the most critical issues facing families across this nation. We salute Senator Warren’s outstanding leadership in the U.S. Senate to advance important legislation to address the drug affordability crisis, including:
The Capping Prescription Costs Act: a bill that would cap out-of-pocket costs for prescription drugs at $250 per month for individuals and $500 per month for families.
The Affordable and Safe Prescription Drug Importation Act: a bill that would allow safe importation of prescription drugs from Canada where drug prices are much lower.
The Affordable Medications Act: a bill that would give Medicare the authority to negotiate lower drug prices and crack down on a range of practices that brand-name and generic drug manufacturers use to keep prices high.
The Medical Innovation Act of 2017, legislation re-introduced by Sen. Warren, would punish drug companies that defraud taxpayers by requiring them to pay a penalty and using the proceeds to fund medical research.